Actively Recruiting
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Led by Shanghai Jiatan Pharmatech Co., Ltd · Updated on 2024-11-25
100
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of WX390 combined with Toripalimab in patients with advanced solid tumors. The main questions it aims to answer are: * the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of WX390; * safety and preliminary in combined therapy. Participants will be treated with WX390 orally and Toripalimab intravenously, and follow the efficacy and safety evaluation according to the protocol.
CONDITIONS
Official Title
A Study of WX390 Combined With Toripalimab in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older
- Histological or cytological confirmed advanced solid tumor with failed standard regimen or no standard regimen available
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Life expectancy greater than 3 months
- At least one measurable lesion according to RECIST 1.1
- Adequate organ function
- Signed and dated informed consent
You will not qualify if you...
- Anti-cancer therapy within 30 days prior to investigational treatment
- Major surgery within 30 days prior to study treatment
- Corticosteroids or other immunodepressant treatment within 2 weeks before first study dose
- Toxicity from previous anti-tumor treatment not resolved to Grade 0 or 1 (except alopecia)
- Active interstitial lung disease
- Ongoing or active serious infection
- History of HIV infection or active hepatitis B or C infection
- Unable to take medication orally
- Alcohol or drug abuse
- Cognitive or psychological abnormalities or low compliance
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the first affiliated hospital of Jilin university
Changchun, Jilin, China, 130000
Actively Recruiting
Research Team
X
Xiaoxue Zhu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here